These findings flag clinical concern regarding the relative non-culprit nature of the coronary arteries in MINOCA presentations. Efforts towards improved medical management are need to eliminate further infarct presentations.
Background: Q fever infection by Coxiella Burnetii was discovered in Australia in 1935. Q fever endocarditis is rare and usually affects patients with native valve abnormalities or those with valve replacements. Diagnosis is difficult as infection is often culture negative. We investigated reported cases of Q fever endocarditis in the literature from 1967 to 2017.
Methods: A literature search for detailed case reports and case series of patients with Q fever endocarditis was performed. Papers were included if cases had positive PCR, valve culture or serology (antiphase IgG titre >1:800 or total complement fixation test total phase 1 antibodies of more than 512). A total of 31 studies from 15 countries were included.
Results: The data show that 78% of patients were male with an average age of 51 years. Native valve abnormalities or the presence of prosthetic cardiac material was present in 84% of patients. Over 76% of patients had a documented history of significant contact with animals or travel. Only 6.5% cases demonstrated positive blood culture for Coxiella Burnetii with 99% of cases confirmed with serology. Doxycycline and Hydroxychloroquine was the most common antibiotic treatment regimen with an average length of treatment of 36 months, 71% of patients required surgery and 23 (17%) deaths were documented.
Conclusions: Our study highlights the importance of serological diagnosis and possible risk factors such as the male gender, pre-existing valvular conditions including prosthetic cardiac material and contact with animals or travel. Background: In type 2 diabetes, the temporal proximity of an atherosclerotic cardiovascular (CV) event can impact prognosis, but whether timing influences sodium glucose co-transporter 2 inhibitor effects is unknown. We explored the association of time from last qualifying CV event before randomization (myocardial infarction [MI], stroke, coronary artery disease or peripheral arterial disease) with CV outcomes and benefit of empagliflozin (EMPA) in EMPA-REG OUTCOME.
Methods: Patients (pts) were randomised to EMPA 10 mg, 25 mg or placebo and followed for 3.1 years (median). Risk of major adverse CV events (3P MACE: CV death, MI, stroke), CV death or hospitalisation for heart failure (HHF) were evaluated using Cox regression in subgroups of ≤1/>1 year since last qualifying CV event. Qualifying event stratification was possible in 6796 (97%) pts.
Results: In the overall population, N = 6796 (4547 EMPA and 2249 placebo pts), median (Q1, Q3) time from last CV event was 3.8 (1.5-7.6) years. Overall, 1214 (EMPA 841; placebo 373) and 5582 (EMPA 3706; placebo 1876) pts had a last qualifying CV event ≤1 and >1 year, respectively. Pts with more recent events had similar risk for CV outcomes compared with pts >1 year from qualifying event. Moreover, the benefit of EMPA on CV outcomes was consistent between pts enrolled ≤1 or >1 year from the qualifying CV event (all p-interaction >0.05).
Conclusion: Although most pts had a qualifying CV event >1 year before randomisation in EMPA-REG OUTCOME, the benefits of EMPA appear to extend to pts with more recent CV events. http://dx.doi.org/10. 1016/j.hlc.2019.06.417 
